NCT04494178

G-PUR® for Reduced Dietary Fumonisin Bioavailability

A Randomized, Placebo-controlled, Double-blind, Cross-over Study to Evaluate the Effect of G-PUR® on Dietary Fumonisin Bioavailability

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Glock Health, Science and Research GmbH · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This prospective, placebo-controlled, randomized, monocentric, double-blind, crossover study in healthy volunteers aims to assess the effect of a single dose of 2 g G-PUR® on bioavailability of dietary fumonisin and to evaluate safety and tolerability.

Conditions

• Reduction of Dietary Fumonisin Bioavailability

Interventions

Type	Name	Description
DEVICE	2.0g G-PUR®	Oral administration (Intervention period I)
DEVICE	2.0g G-PUR®	Oral administration (Intervention period II)
OTHER	Placebo	Intervention period I
OTHER	Placebo	Intervention period II

Timeline

• Start date: 2020-08-18
• Primary completion: 2020-11-04
• Completion: 2020-11-04
• First posted: 2020-07-31
• Last updated: 2020-11-16

Locations

1 site across 1 country: Austria